Kidney Cancer Drugs Market Report and Forecast 2025-2034

The kidney cancer drugs market was valued at USD 7.09 Billion in 2024 driven by rising global incidence of renal cell carcinoma (RCC) and increasing adoption of immuno-oncology therapies across 8 major markets. It is expected to grow at a CAGR of 6.30% during the forecast period of 2025-2034 and attain a market value of USD 13.06 Billion by 2034. Additionally, expanding treatment access across emerging markets, regulatory support for rare subtypes like translocation RCC, and the development of novel drug combinations that address resistance mechanisms are further strengthening the market’s growth prospects in the coming years.

Kidney Cancer Drugs Market Overview

Kidney cancer, also known as renal cancer, originates in the kidneys and includes several types, with renal cell carcinoma (RCC) being the most common, accounting for about 90% of cases. Other types include transitional cell carcinoma, Wilms tumor (in children), and renal sarcoma. Treatment depends on the stage and type, ranging from surgery to targeted therapies and immunotherapies. Common drugs include tyrosine kinase inhibitors (like sunitinib and sorafenib), immune checkpoint inhibitors (like nivolumab), and combination regimens, which have improved survival rates for advanced and metastatic kidney cancer cases. The market is expected to grow at a CAGR of 6.30% during the forecast period of 2025-2034

Kidney Cancer Drugs Market Growth Drivers

Patient-Focused Research Boosting Market Growth

The increasing demand for precision therapies and patient-driven innovation is a significant market driver. For instance, in March 2025, Dana‑Farber and Broad Institute launched a new Count Me In patient‑partnered study targeting translocation RCC (tRCC), a rare aggressive subtype. By engaging patients directly for genomic and clinical data sharing, the initiative enhances understanding of tRCC’s molecular drivers and accelerates drug discovery pipelines. This collaborative model is expected to fast-track therapeutic development, expanding the kidney cancer drugs market through the forecast period with more targeted and effective treatment options.

Personalized Vaccine Breakthroughs to Enhance Kidney Cancer Drugs Market Value

The increasing focus on immunotherapies and adjuvant treatments is fueling market expansion. For instance, in February 2025, Dana‑Farber reported that nine stage III/IV clear cell RCC patients, treated with a personalized neoantigen vaccine following surgery, remained cancer‑free after 34.7 months and showed robust T‑cell responses (166‑fold increase). These early yet promising results signal a paradigm shift toward personalized vaccines in renal cell carcinoma management, likely driving demand for novel cancer drugs and enriching the pipeline with innovative immune-based therapies during the forecast period.

Kidney Cancer Drugs Market Trends

Major market trends include growing disease incidence, therapeutic innovations, and expanding clinical trials.

Rising Incidence Strengthening the Drug Demand for Kidney Cancer

The growing global burden of renal cell carcinoma (RCC), which accounts for about 90% of kidney cancers, is significantly driving demand for targeted kidney cancer therapies. For instance, in 2025, the United States is projected to report approximately 80,980 new cases and 14,510 deaths from kidney and renal pelvis cancers. RCC contributes to over 400,000 new cases and nearly 175,000 deaths annually. This rising disease prevalence is poised to bolster market growth as healthcare systems prioritize advanced treatments to manage this growing oncological threat.

Innovative Combination Therapies to Advance Kidney Cancer Drugs Market Value

The advancements in combination immunotherapies and tyrosine kinase inhibitors are reshaping the treatment landscape for kidney cancer. For instance, in March 2025, Exelixis presented promising results from the phase 1b/2 STELLAR-002 trial evaluating zanzalintinib with nivolumab or Opdualag in untreated advanced clear cell RCC patients. These early findings, unveiled at ASCO 2025, highlight improved tolerability and therapeutic potential. Such novel combinations are expected to strengthen the kidney cancer drugs market through expanded treatment options and enhanced clinical outcomes.

Increasing Regulatory Approvals of Targeted Therapies Boosting Potential for Kidney Cancer Drugs Market Growth

The rising focus on high-risk, treatment-resistant patient groups is propelling targeted drug development for kidney cancer. For instance, in March 2025, the FDA accepted an IND application to launch Oncorella-1, a dual-phase trial assessing ONC175 (orellanine) for metastatic RCC patients on dialysis. The trial spans both the US and Sweden, enrolling up to 75 patients. With a novel approach for dialysis-dependent RCC, ONC175 could open new avenues, supporting drug market growth through niche therapeutic innovation.

Expanding Clinical Trials to Accelerating Kidney Cancer Drugs Market Growth

The growing number of clinical trials for kidney cancer is accelerating drug discovery and therapeutic validation. Pharmaceutical firms and research institutions are increasingly collaborating to explore novel agents, biomarkers, and treatment combinations. This trend is enhancing drug pipelines and promoting early patient access to cutting-edge therapies. As more multi-phase trials progress toward regulatory milestones, the kidney cancer drugs market is expected to witness robust development through an influx of clinically backed, next-generation treatment options.

Kidney Cancer Drugs Market Segmentation

The market report offers a detailed analysis of the market based on the following segments:

Market Breakup by Therapy

• Targeted Therapy
• Chemotherapy
• Immunotherapy

Market Breakup by Drug Class

• Anti-Angiogenesis
• mTOR Inhibitors
• Interleukin
• Immune Checkpoint Inhibitors

Market Breakup by Indication

• Renal Cell Carcinoma
• Urothelial Carcinoma
• Others

Market Breakup by Distribution Channel

• Hospital
• Specialty and Retail Pharmacies
• Others

Market Breakup by Region

• United States
• United Kingdom
• Germany
• France
• Italy
• Spain
• Japan
• India

Kidney Cancer Drugs Market Share

Immune Checkpoint Inhibitors Dominating the Segment by Drug Class

Immune checkpoint inhibitors are expected to hold the largest market share due to their proven efficacy in treating advanced renal cell carcinoma and improving overall survival. These therapies, such as nivolumab and pembrolizumab, work by enhancing the immune system’s ability to target cancer cells. Their growing use in first-line and combination treatments, along with ongoing clinical advancements, positions this segment for strong growth. Increasing regulatory approvals and adoption in treatment guidelines further reinforce its leading role in the market.

Kidney Cancer Drugs Market Analysis by Region

United States and Japan Leading the Kidney Cancer Drugs Market by Region

The United States is poised to dominate the market due to its high disease burden, cutting-edge immunotherapy approvals, and strong oncology R&D ecosystem. It is expected to see nearly 81,000 new kidney cancer cases in 2025, driving drug demand. Japan is expected to follow closely, supported by a rapidly aging population and high healthcare spending. In 2022, Japan experienced 21,207 new cases of kidney cancer, highlighting the increasing burden of the market. Early integration of combination therapies and robust post-marketing surveillance also contributes to Japan’s growing influence in the kidney cancer treatment landscape.

Leading Players in the Kidney Cancer Drugs Market

The key features of the market report comprise patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Active Biotech AB

Active Biotech AB, founded in 1998 and headquartered in Lund, Sweden, is a biotechnology company focused on the development of immunomodulatory drugs for the treatment of cancer and inflammatory diseases. In the kidney cancer drugs market, the company is recognized for developing laquinimod and tasquinimod, both aimed at targeting tumor growth and microenvironments. With a strong emphasis on innovative therapies, Active Biotech continues to contribute to the advancement of novel treatments in the oncology space, including renal cell carcinoma.

Amgen

Established in 1980 and based in Thousand Oaks, California, Amgen is a global biopharmaceutical leader known for its pioneering work in biotechnology and oncology. The company’s kidney cancer portfolio includes the development and marketing of targeted therapies, such as tivozanib and investigational agents focused on angiogenesis inhibition and immunotherapy combinations. Through extensive R&D efforts and strategic collaborations, Amgen continues to expand its oncology pipeline, aiming to address unmet clinical needs in renal cell carcinoma and related cancers.

Bayer AG

Headquartered in Leverkusen, Germany, and founded in 1863, Bayer AG is a life sciences giant with a robust pharmaceuticals division, including oncology. In the kidney cancer space, Bayer is known for developing drugs like Nexavar (sorafenib) and Stivarga (regorafenib), both tyrosine kinase inhibitors approved for various cancers, including advanced renal cell carcinoma. The company continues to invest in innovative therapies and clinical trials to enhance treatment outcomes and maintain its strong foothold in the kidney cancer drugs market.

Cipla Limited

Cipla Limited, founded in 1935 and headquartered in Mumbai, India, is a leading global pharmaceutical company with a strong presence in generics and specialty medicines. In the kidney cancer segment, Cipla offers cost-effective generic versions of key cancer therapeutics, including sorafenib, enhancing access to affordable treatment options. The company actively supports oncology care across emerging markets and is committed to expanding its oncology portfolio through partnerships, R&D, and biosimilar launches to address the growing burden of renal cancers.

Other key players in the market include F. Hoffmann-La Roche AG, GSK plc, Novartis AG, Pfizer Inc., Astellas Pharma, Bristol-Myers Squibb Company, Eisai Co., Ltd., and Merck & Co., Inc., among others.

Key Questions Answered in the Kidney Cancer Drugs Market

• What was the kidney cancer drugs market value in 2024?
• What is the kidney cancer drugs market forecast outlook for 2025-2034?
• What are the major factors aiding the kidney cancer drugs market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major kidney cancer drugs market trends?
• Which therapy will lead the market segment?
• Which drug class will lead the market segment?
• Which indication will lead the market segment?
• Which distribution channel will lead the market segment?
• Who are the key players involved in the kidney cancer drugs market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?